No Data
No Data
Express News | Sonnet BioTherapeutics Q2 EPS $(0.89) Misses $(0.79) Estimate
Sonnet BioTherapeutic | 10-Q: Quarterly report
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Sonnet BioTherapeutics Discusses Positive Safety Data for SON-1010 in Virtual Investor Segment
Sonnet BioTherapeutics Price Target Maintained With a $20.00/Share by Chardan Capital
Sonnet BioTherapeutics Is Maintained at Buy by Chardan Capital